Company Overview
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 30.4%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $2.98M (-33.5% YoY); net profit $-148.65M.
- Trailing 12 Months Year-on-year growth — revenue -33.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -33.45% |
Stock Price Performance
| 1 Year: | +64.25% |
| 6 Months: | - |
| 3 Months: | +57.54% |
| 1 Month: | +27.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)62.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.4%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ODTX Odyssey Therapeutics, Inc. PHARMA | 26.97 | -8.07 | $1.30B | 0.00% | -66.23% | 30.44% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.75M | 1.92M | 959.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 38.88M | 46.73M | - | 39.67M | - |
| Operating Income | -37.12M | -44.81M | -41.92M | -39.67M | -55.47M |
| EBITDA | -34.59M | -36.99M | - | -37.02M | - |
| Interest Expense | 4.00K | 2.00K | - | 10.00K | - |
| Pretax Income | -35.88M | -38.30M | - | -38.20M | - |
| Tax Provision | 47.00K | 140.00K | - | 63.00K | - |
| Net Income | -35.93M | -38.44M | -41.23M | -38.26M | -52.79M |
| Diluted EPS | - | -1.39 | -29.54 | -0.81 | -1.74 |
| R&D Expense | - | 38.77M | 30.23M | 32.32M | 36.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 1.04M | 4.47M | 2.98M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 122.78M | 134.48M | 139.69M | 164.13M |
| Operating Income | -122.78M | -133.44M | -135.22M | -161.16M |
| EBITDA | -121.26M | -120.25M | -123.64M | -144.65M |
| Interest Expense | 291.00K | 335.00K | 18.00K | 17.00K |
| Pretax Income | -124.32M | -125.49M | -128.85M | -149.57M |
| Tax Provision | 347.00K | 447.00K | 469.00K | -927.00K |
| Net Income | -124.67M | -125.94M | -129.32M | -148.65M |
| Diluted EPS | -4.52 | -1.32 | -4.73 | -5.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 317.15M | 286.52M | 197.44M | 269.79M |
| Current Assets | 248.71M | 192.54M | 135.51M | 190.66M |
| Cash & Equivalents | 241.04M | 52.55M | 59.14M | 41.69M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 461.77M | 549.23M | 579.96M | 758.07M |
| Current Liabilities | 22.80M | 22.09M | 28.41M | 26.48M |
| Long Term Debt | 4.76M | - | - | - |
| Total Debt | 42.49M | 34.38M | 31.01M | 27.11M |
| Total Equity | -144.62M | -262.71M | -382.53M | -488.28M |
| Shares Outstanding | 47.17M | 47.17M | 47.17M | 47.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -99.84M | -112.73M | -117.47M | -129.47M |
| Investing Cash Flow | -13.03M | -165.02M | 96.78M | -103.94M |
| Financing Cash Flow | 182.72M | 92.08M | 26.98M | 215.65M |
| Capital Expenditure | -13.03M | -5.06M | -764.00K | -1.23M |
| Free Cash Flow | -112.87M | -117.78M | -118.23M | -130.70M |
| Net Change in Cash | 69.85M | -185.67M | 6.29M | -17.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | -12,867.8% | -3,023.8% | -5,415.2% |
| Net Margin % | - | -12,144.5% | -2,891.8% | -4,994.9% |
| ROE % | 86.2% | 47.9% | 33.8% | 30.4% |
| ROCE % | -41.7% | -50.5% | -80.0% | -66.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 10.78% | 5.18M | $126.27M |
| 2 | SR One Capital Management, LP | 7.90% | 3.79M | $92.52M |
| 3 | TPG GP A, LLC | 7.68% | 3.69M | $89.97M |
| 4 | Lightspeed Management Company, L.L.C. | 7.51% | 3.61M | $87.97M |
| 5 | Orbimed Advisors LLC. | 6.24% | 3.00M | $73.17M |
| 6 | Sanofi | 4.14% | 1.99M | $48.56M |
| 7 | Deerfield Management Company, L.P | 2.18% | 1.05M | $25.50M |
| 8 | Sands Capital Alternatives, LLC | 1.82% | 875.00K | $21.33M |
| 9 | HHLR Advisors, LTD | 1.73% | 831.66K | $20.28M |
| 10 | General Catalyst Group Management, LLC | 1.69% | 810.27K | $19.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ODTX
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPV2RLcENSR1VkUHNJZnZ4ZTNfSlJ6YWdDR05aWldyTm43aS1mMjRoQUFlbFJ5bU1lRXh2SEZTNnZYN01MLUJNSUc3bVpBTkk0eVVYRk40d2c2NWVIZUJXaHFJaFMtcG9ZeXF5VHMzdzV4NXpTcHg5UEJpaHV2ZEtZcnA4c1RrVF9fdUVSN1…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFAxeHo3U0cxaWxuREZUa1RqdWtCci05VjcybDdrcGl3U1NlTk56dWQ1S1BHZmhSRUgtNzRycTVDMlQ0eF9McHNUUF85aHBlR1dI?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
ODTX Stock Price and Chart — NASDAQ:ODTX - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9YMTZ0VlFxNXpHYU1XRHQ0b0s1eWhHdjFwNUZNU01TWEV0Wkx1Q2RGaHRqYnNGZWVVZ2QxWUlvNHBLUHZHVURJT3E0MnNxQ094NFNRSFhLRjBDa1ZH?oc=5" target="_blank">ODTX Stock Price and Chart — NASDAQ:ODTX</a…
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOYWkwdXc5dlJMMlFkeC1KSmhuNUhfUzhtT1ZKRFVpUm9hZUlPenNmbklZSENPbG9UazBFRnhoc1hjUDFKRVFnVEF6NkNvaXh4eFdlTzh4NGJWbmdKM2x6UVBrOGxSRFgxWFRUeHd4YTBzRk52R3RnQU5RbzlZdGlManVMOTZqWmdLNGJVSF…
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOMTFjTlp3QnhLbnBNbGVHdENPeDEwdWxCX2k0OHZYTkFITW13b1JDT3RDempOQVVpbFR1SDFNUnZ3T0xid2V6eEd4QW1zR2k2Y0tlajRDQUJSXzZKMDBPVktrdWRhRUFLVG54ZGNsTWFzeUhWcTliRm5KQV8xM3JBeElINHdxVGhaV3JiZk…
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1ERXB4TkJ1TE45V2tHQ2hjSEU1NHpaN29SaHBERFBFWHpILTgzS0huWElJc1F2Vmg4aENhWlpzR3Iwd1FOS2VkaVFFSjhaY1BnUjZpSUlR?oc=5" target="_blank">Odyssey Therapeutics, Inc. Common Stock (NASDAQ: OD…
ODTX — Frequently Asked Questions
What is the current share price of Odyssey Therapeutics, Inc. (ODTX)?
As of 2026-09-19 21:16 PDT, Odyssey Therapeutics, Inc. (ODTX) trades at $26.97 on NasdaqCM. Its 52-week range is $15.56 to $28.76.
What is the market capitalisation of ODTX?
Odyssey Therapeutics, Inc. (ODTX) has a market capitalisation of $1.30B on NasdaqCM.
What is the P/E ratio of ODTX?
ODTX trades at a trailing price-to-earnings (P/E) ratio of -8.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.77.
What is the return on equity (ROE) of ODTX?
ODTX has a return on equity (ROE) of 30.44%. Its return on capital employed (ROCE) is -66.23%.
Is ODTX a good stock to buy?
This page provides a data-driven analysis of Odyssey Therapeutics, Inc. (ODTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.